In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data Shows ...

Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The ...

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out. Image source: Getty Images. Viking's ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), PepsiCo, Inc. (PEP) and Morgan Stanley (MS).

Also Read: Eli Lilly’s Zepbound/Moun President-elect Trump’s decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly ...